1
|
Hwang JH, Spurlock ME, Kube JC, Li XZ, Smith SB. Characterization of β-adrenergic receptors in bovine intramuscular and subcutaneous adipose tissue: comparison of lubabegron fumarate with β-adrenergic receptor agonists and antagonists. J Anim Sci 2021; 99:6333505. [PMID: 34337647 PMCID: PMC8326056 DOI: 10.1093/jas/skab116] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Accepted: 04/13/2021] [Indexed: 11/29/2022] Open
Abstract
Chinese hamster ovary cell constructs expressing either the β 1-, β 2- or β 3-adrenergic receptor (AR) were used to determine whether a novel β-AR modulator, lubabegron fumarate (LUB; Experior, Elanco Animal Health) might exert greater potency for a specific β-AR subtype. EC50 values calculated based on cAMP accumulation in dose response curves indicate that LUB is highly selective for the β 3-AR subtype, with an EC50 of 6 × 10–9 M, with no detectible agonistic activity at the β 2-AR. We hypothesized that the accumulation of lipolytic markers would reflect the agonist activity at each of the β-receptor subtypes of the specific ligand; additionally, there would be differences in receptor subtype expression in subcutaneous (s.c.) and intrmuscular (i.m.) adipose tissues. Total RNA was extracted from adipose tissue samples and relative mRNA levels for β 1-, β2-, and β 3-AR were measured using real-time quantitative polymerase chain reaction. Fresh s.c. and i.m. adipose tissue explants were incubated with isoproterenol hydrochloride (ISO; β-AR pan-agonist), dobutamine hydrochloride (DOB; specific β 1-AA), salbutamol sulfate (SAL; specific β 2-AA), ractopamine hydrochloride (RAC), zilpaterol hydrochloride (ZIL), BRL-37344 (specific β 3-agonist), or LUB for 30 min following preincubation with theophylline (inhibitor of phosphodiesterase). Relative mRNA amounts for β 1-, β 2-, and β 3-AR were greater (P < 0.05) in s.c. than in i.m. adipose tissue. The most abundant β-AR mRNA in both adipose tissues was the β 2-AR (P < 0.05), with the β 1- and β 3-AR subtypes being minimally expressed in i.m. adipose tissue. ISO, RH, and ZH stimulated the release of glycerol and nonesterified fatty acid (NEFA) from s.c. adipose tissue, but these β-AR ligands did not alter concentrations of these lipolytic markers in i.m. adipose tissue. LUB did not affect glycerol or NEFA concentrations in s.c. or i.m. adipose tissue, but attenuated (P < 0.05) the accumulation of cAMP mediated by the β 1- and β 2-AR ligands DOB and SAL in s.c. adipose tissue. Collectively, these data indicate that bovine i.m. adipose tissue is less responsive than s.c. adipose tissue to β-adrenergic ligands, especially those that are agonists at the β 1- and β3-receptor subtypes. The minimal mRNA expression of the β 1- and β 3 subtypes in i.m. adipose tissue likely limits the response potential to agonists for these β-AR subtypes.
Collapse
Affiliation(s)
- Jinhee H Hwang
- Department of Animal Science, Texas A&M University, College Station, TX 77843, USA
| | | | - John C Kube
- Elanco Animal Health, 2500 Innovation Way, Greenfield, IN 46140, USA
| | - Xiang Z Li
- Department of Animal Science, Texas A&M University, College Station, TX 77843, USA
| | - Stephen B Smith
- Department of Animal Science, Texas A&M University, College Station, TX 77843, USA
| |
Collapse
|
2
|
Abstract
The β-3 adrenergic receptor (ADRB3) is a G-protein coupled receptor involved in regulating lipolysis, as part of homeostatic regulation. In this study, South African Mutton Merino and Shanxi Dam Line were used to study the distribution and quantification of ADRB3 in adipose (subcutaneous, omental, retroperitoneal, mesenteric and perirenal fat) and non-adipose (heart, liver, spleen, lung and kidney) tissues of sheep. The protein was determined by immunohistochemical technique and by mRNA abundance via real-time polymerase chain reaction. ADRB3 was detected in all studied tissues with abundance in adipose tissues higher than in non-adipose tissues (P < 0.001). For adipose tissues, greater expression was found in deep deposits such as great omental and retroperitoneal fat than in subcutaneous fat (P < 0.05). Significant differences (P < 0.05) both for mRNA and for protein expression also existed between the two sheep flocks. These findings are consistent with the known function of ADRB3 in mediating lipolysis and homeostasis in adipose tissues.
Collapse
|
3
|
Samadi, Jois M, Dunshea FR, Leury BJ. The β3-adrenergic agonist (BRL35135A) acutely increases oxygen consumption and plasma intermediate metabolites in sheep. ANIMAL PRODUCTION SCIENCE 2011. [DOI: 10.1071/an10019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
There is evidence that an atypical adrenoreceptor subtype is involved in mediating some of the physiological effects of catecholamines, particularly in some adipose tissue sites. Therefore, three experiments were conducted to determine the metabolic and energetic responses to oral administration of the purported β3-agonist BRL35135A in ruminant lambs. The post-prandial increase in O2 consumption (0.109 versus 0.139 L/min) and CO2 production (0.102 versus 0.127 L/min) at 30 min after feeding was greater (P < 0.05) in the lambs receiving 5 mg of the BRL35135A. Treatment × time interactions over the period between –50 and 220 min indicate significant increases in plasma non-esterified fatty acids (P < 0.001), glucose (P < 0.001) and lactate (P = 0.024) in lambs consuming a single oral dose of 5 mg BRL35135A. In a subsequent experiment there were similar interactions over the period between –120 and 1440 min for non-esterified fatty acids (P < 0.001), glucose (P < 0.001) and lactate (P < 0.001) in lambs consuming a lower oral dose of 1 mg BRL35135A. The effects of BRL35135A on plasma non-esterified fatty acids (P = 0.95), glucose (P = 0.84) and lactate (P = 0.68) were not modified by the β1- and β2-adrenergic antagonist alprenolol suggesting that the effects were mediated via β3-adrenergic receptor subtypes. In conclusion, these experiments indicate that BRL35135A is acutely active in sheep when given with feed, as indicated by increases in respiratory gas exchange and plasma metabolite concentrations.
Collapse
|
4
|
Moens AL, Yang R, Watts VL, Barouch LA. Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system. J Mol Cell Cardiol 2010; 48:1088-95. [PMID: 20184889 DOI: 10.1016/j.yjmcc.2010.02.011] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2009] [Revised: 12/08/2009] [Accepted: 02/12/2010] [Indexed: 11/18/2022]
Abstract
The presence of a third beta-adrenergic receptor (beta 3-AR) in the cardiovascular system has challenged the classical paradigm of sympathetic regulation by beta1- and beta2-adrenergic receptors. While beta 3-AR's role in the cardiovascular system remains controversial, increasing evidence suggests that it serves as a "brake" in sympathetic overstimulation - it is activated at high catecholamine concentrations, producing a negative inotropic effect that antagonizes beta1- and beta2-AR activity. The anti-adrenergic effects induced by beta 3-AR were initially linked to nitric oxide (NO) release via endothelial NO synthase (eNOS), although more recently it has been shown under some conditions to increase NO production in the cardiovascular system via the other two NOS isoforms, namely inducible NOS (iNOS) and neuronal NOS (nNOS). We summarize recent findings regarding beta 3-AR effects on the cardiovascular system and explore its prospective as a therapeutic target, particularly focusing on its emerging role as an important mediator of NO signaling in the pathogenesis of cardiovascular disorders.
Collapse
Affiliation(s)
- An L Moens
- Johns Hopkins University School of Medicine, Division of Cardiology, Baltimore, MD 21205, USA
| | | | | | | |
Collapse
|
5
|
Soret B, Melrose SE, Finley E, Vernon RG. Differential control of lipogenesis and lipolysis during development of ovine preadipocytesin vitro. ACTA ACUST UNITED AC 2007. [DOI: 10.1079/asc200657] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
AbstractThe stromovascular fraction of adipose tissue from sheep, like that of other species, contains preadipocytes which can be induced to differentiate in culture, providing a potentially useful system for studying adipocyte development. Differentiation of ruminant preadipocytes has only been partly characterized previously so we have investigated the factors regulating the development of lipogenesis and lipolysis in sheep cells. Insulin, rosiglitazone (a peroxisome proliferation activated receptor-γ agonist) and either dexamethasone or a lipid suplement are required during differentiation for maximum rates of lipogenesis, whereas all four components are required to achieve maximum rates of catecholamine-stimulated lipolysis. Tri-iodothyronine had no effect on the development of lipogenesis but resulted in a reduced rate of catecholamine-stimulated lipolysis. Lipogenesis and lipolysis also differed in that the rate of lipogenesis increased to a maximum at about 10 days of differentiation and then fell, whereas the rate of lipolysis reached a plateau at about 10 days. By contrast to catecholamine-stimulated lipolysis, there is little or no evidence for development of the adenosine-based antilipolytic system; this may be because response to adenosine develops very late during preadipocyte differentiation or additional, unidentified factors are required to induce this antilipolytic system. Lipogenesis in differentiated preadipocytes responded to both insulin and growth hormone. These studies show that the development of lipogenesis and lipolysis are under distinct control systems. Furthermore, while preadipocytes differentiatedin vitroshow many of the characteristics of adipocytes differentiatedin vivo, there are still significant differences.
Collapse
|
6
|
|
7
|
Sillence MN. Technologies for the control of fat and lean deposition in livestock. Vet J 2004; 167:242-57. [PMID: 15080873 DOI: 10.1016/j.tvjl.2003.10.020] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/29/2003] [Indexed: 11/16/2022]
Abstract
When the ratio of lean to fat deposition is improved, so is feed conversion efficiency. Net benefits may include lower production costs, better product quality, less excretion of nitrogenous wastes into the environment, decreased grazing pressure on fragile landscapes, and reduced pressure on world feed supplies. However, finding a way to achieve these goals that is reliable, affordable, and acceptable to the majority of consumers has proved to be a major challenge. Since the European Union banned hormonal growth promoters (HGPs) 15 years ago, countries such as Australia and the United States have licensed new products for livestock production, including bovine growth hormone (GH), porcine and equine GH, and the beta-agonist ractopamine. There has also been considerable research into refining these products, as well as developing new technologies. Opportunities to improve beta-agonists include lessening their effects on meat toughness, reducing adverse effects on treated animals, and prolonging their duration of action. In the last regard, the combined use of a beta-agonist with GH, which upregulates beta-adrenoceptors, can produce an outstanding improvement in carcass composition and feed efficiency. Insulin-like growth factor-1 (IGF-1) mediates many of the actions of GH, but has proved to be of more use as a growth reporter/selection marker in pigs, than as a viable treatment. However, a niche for this product could exist in the manipulation of neonatal growth, causing a life-long change in lean:fat ratio. Another significant advance in endocrinology is the discovery of hormones secreted by muscle and fat cells, that regulate feed intake, energy metabolism, and body composition. Leptin, adiponectin and myostatin were discovered through the study of genetically obese, or double-muscled animals. Through genetic manipulation, there is potential to exploit these findings in a range of livestock species, although the production of transgenic animals is still hampered by the poor level of control over gene expression, and faces an uphill battle over consumer acceptance. There are several alternatives to HGPs and transgenics, that are more likely to gain world-wide acceptance. Genetic selection can be enhanced by using markers for polymorphic genes that control fat and lean, such as thyroglobulin, or the callipyge gene. Feed additives of natural origin, such as betaine, chromium and conjugated linoleic acid, can improve the fat:lean ratio under specific circumstances. Additionally, 'production vaccines' have been developed, which alter the neuro-endocrine system by causing an auto-immune response. Thus, antibodies have been used to neutralise growth-limiting factors, prolong the half-life of anabolic hormones, or activate hormone receptors directly. Unfortunately, none of these technologies is sufficiently well advanced yet to rival the use of exogenous HGPs in terms of efficacy and reliability. Therefore, further research is needed to find ways to control fat and lean deposition with due consideration of industry needs, animal welfare and consumer requirements.
Collapse
Affiliation(s)
- M N Sillence
- School of Agriculture, Charles Sturt University, Locked Bag 588, Wagga Wagga, NSW 2678, Australia.
| |
Collapse
|
8
|
Inderwies T, Pfaffl MW, Meyer HHD, Blum JW, Bruckmaier RM. Detection and quantification of mRNA expression of alpha- and beta-adrenergic receptor subtypes in the mammary gland of dairy cows. Domest Anim Endocrinol 2003; 24:123-35. [PMID: 12586313 DOI: 10.1016/s0739-7240(02)00211-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Adrenergic receptors are pharmacologically classified into the receptor types alpha(1), alpha(2), beta(1), beta(2), and beta(3). Structural differences and varying affinities in radioligand binding studies lead to a further classification of alpha(1)- and alpha(2)-receptors into subtypes which are termed alpha(1A) (formerly alpha(1C)), alpha(1B), and alpha(1D) (formerly alpha(1AD)), and alpha(2AD), alpha(2B), and alpha(2C), respectively. mRNA expression of all but one alpha-adrenergic receptor subtypes and of all beta-adrenergic receptor types was measured quantitatively in total RNA extracted from mammary tissue of 10 lactating dairy cows by real-time reverse transcription (RT) polymerase chain reaction (PCR). mRNA expression of alpha(1)-adrenergic receptors was highest for the alpha(1A)-subtype followed by alpha(1B), whereas the alpha(1D)-subtype could not be detected. The highest mRNA expression of alpha(2)-adrenergic receptors was found for the alpha(2AD)-subtype, followed by alpha(2B) and alpha(2C). Within the beta-adrenergic receptors, the beta(2)-receptor type was most highly expressed, followed by beta(1) and beta(3). In conclusion, eight of nine adrenergic receptors classified to date were detected and relatively quantified in the mammary gland of dairy cows.
Collapse
MESH Headings
- Animals
- Base Sequence
- Cattle
- Female
- Humans
- Lactation
- Mammary Glands, Animal/chemistry
- RNA, Messenger/analysis
- Receptors, Adrenergic, alpha/genetics
- Receptors, Adrenergic, alpha-1/genetics
- Receptors, Adrenergic, alpha-2/genetics
- Receptors, Adrenergic, beta/genetics
- Receptors, Adrenergic, beta-1/genetics
- Receptors, Adrenergic, beta-2/genetics
- Receptors, Adrenergic, beta-3/genetics
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
Affiliation(s)
- T Inderwies
- Institute of Physiology, Technical University Munich, D-85354 Freising-Weihenstephan, Germany
| | | | | | | | | |
Collapse
|
9
|
Donckier JE, Massart PE, Van Mechelen H, Heyndrickx GR, Gauthier C, Balligand JL. Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. Eur J Clin Invest 2001; 31:681-9. [PMID: 11473569 DOI: 10.1046/j.1365-2362.2001.00872.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND A new beta 3-adrenoceptor (beta3-AR) has been shown to mediate peripheral vasodilation. This study was conducted to evaluate effects of the beta3-AR agonist, SR58611 in normal and hypertensive dogs. MATERIALS AND METHODS In protocol 1, SR58611 was infused in normal dogs after placebo, after beta1/beta2 blockade with nadolol, after beta1/beta2/beta3 blockade with bupranolol and after combined autonomic blockade (CAB). In protocol 2, perinephritic hypertension was produced in dogs, which received SR58611 at 3 and 6 weeks of hypertension. Effects of SR58611 were evaluated at 7 weeks of hypertension after CAB. RESULTS In normal dogs, SR58611 produced a dose-dependent decrease in mean aortic pressure (AOP) (from 116 +/- 19 to 100 +/- 19 mmHg, - 14%; P < 0.05) that was accompanied by baroreflex activation (heart rate increased by 70%; P < 0.01). This hypotensive effect resulting from peripheral vasodilation persisted after nadolol or CAB while baroreflex activation was blunted or abolished. A biphasic response of cardiac output, characterized by a rise and a decline (P < 0.05) reflected a reduction in after- and pre-load. After CAB, SR58611 did not modify cardiac contractility. SR58611 stimulated lipolysis as reflected by a 4-fold increase in blood free fatty acids (FFA) (P < 0.0005). Under CAB, the rise of FFA was reduced (P < 0.01). In hypertensive dogs, SR58611 produced a dose-dependent decrease in mean AOP (from 168 +/- 32 to 125 +/- 35 mmHg; - 26%, P < 0.0001), that was greater than in normal dogs (P < 0.05). Reflex-mediated tachycardia also occurred but at higher blood pressure values. Blood FFA rose similarly (P < 0.0001). Under CAB, heart rate remained unchanged but SR58611 still induced a decrease (P < 0.0001) in mean AOP concomitantly with a rise of (dP/dt)/DP40 (P < 0.005), an effect not observed in normal dogs. CONCLUSIONS Beta3-AR stimulation exerts hypotensive effects, increases cardiac contractility and stimulates lipolysis in hypertensive dogs.
Collapse
Affiliation(s)
- J E Donckier
- Division of Internal Medicine and Endocrinology, University Hospital of Mont-Godinne, Yvoir, Belgium.
| | | | | | | | | | | |
Collapse
|
10
|
Gauthier C, Leblais V, Moniotte S, Langin D, Balligand JL. The negative inotropic action of catecholamines: Role of β3-adrenoceptors. Can J Physiol Pharmacol 2000. [DOI: 10.1139/y00-045] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
There is now evidence for the involvement of four β-adrenoceptor populations in the regulation of cardiac function by catecholamines. β1- and β2-adrenoceptor stimulation classically produces an increase in contractility. A fourth β-adrenoceptor, as yet uncloned and designated provisionally as a β4-adrenoceptor, also mediates a positive inotropic effect. β3-adrenoceptors, which had been cloned at the end of the eighties, has been extensively studied as a potential target for antiobesity and antidiabetic drugs. Its characterization in the heart has opened new fields of investigations for the understanding of the cardiac adrenergic regulation. This review describes the cardiac electrical and mechanical effects induced by β3-adrenoceptor stimulation in different species (including human), as well as the signaling pathway. It also analyzes the role of these receptors in the abnormal responsiveness of catecholamines in heart failure.Key words: beta-adrenoceptor, heart, contractility, signaling pathway, heart failure.
Collapse
|
11
|
Lenzen G, Pietri-Rouxel F, Drumare MF, Amiard A, Guillot S, Archimbault P, Strosberg AD. Genomic cloning and species-specific properties of the recombinant canine beta3-adrenoceptor. Eur J Pharmacol 1998; 363:217-27. [PMID: 9881593 DOI: 10.1016/s0014-2999(98)00809-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
A molecular clone encoding a beta3-adrenoceptor was isolated from a canine genomic library. The cloned receptor exhibited a pharmacological profile similar to that of other species: in particular, high efficiency of the two selective beta3-adrenoceptor agonists, CL 316,243 (disodium(R,R)-5[2[[2-(chlorophenyl)-2hydroxyethyl]-amino]propyl]- 1,3-benzodioxole-2,2-dicarboxylate) and ICI 201651 ((R)4-(2-hydroxy-3-phenoxypropylaminoethoxy)-N-(2-methoxyethyl)phe noxy acetic acid) and a low affinity for the radioligand (-)-[3-(125)I]-iodocyanopindolol. Interestingly, CGP 12177A ((+/-)-4-(3-t-butylamino-2-hydroxypropoxy)benzimidazol-2-one), which is described as a partial agonist for the human receptor, was a full agonist for the canine receptor. After expression and stimulation of the canine beta3-adrenoceptor in stably transfected Chinese hamster ovary cells there was a very low accumulation of cAMP, suggesting weak coupling to Gs-protein and adenylyl cyclase. However, the response was much better in human embryonal kidney cells transfected with the canine beta3-adrenoceptor gene. The cloning of the canine beta3-adrenoceptor and the insights gained from its pharmacological characterization may allow the development of selective compounds for use in the treatment of obese dogs.
Collapse
|
12
|
Galitzky J, Langin D, Verwaerde P, Montastruc JL, Lafontan M, Berlan M. Lipolytic effects of conventional beta 3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta 4-adrenoceptor. Br J Pharmacol 1997; 122:1244-50. [PMID: 9401793 PMCID: PMC1565062 DOI: 10.1038/sj.bjp.0701523] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
1. The nature of rat and human fat cell beta 3-adrenoceptors was investigated by studying the effects of the new beta 3-adrenoceptor selective antagonist, SR 59,230A, on lipolysis induced by the conventional beta 3-adrenoceptor agonists, CL 316,243 and SR 58,611A, and by the non-conventional partial beta 3-adrenoceptor agonist CGP 12,177 (a potent beta 1- and beta 2-adrenoceptor antagonist with partial beta 3-adrenoceptor agonist property). 2. In rat fat cells, the rank order of potency of agonists was: CL 316,243 > isoprenaline > SR 58,611A > CGP 12,177. The three former agents were full agonists whereas CGP 12,177 was a partial agonist (intrinsic activity of 0.70). In human fat cells, the lipolytic effect of CGP 12,177 reached 25% of isoprenaline effect. CL 316,243 was a poor inducer of lipolysis and SR 58,611A was ineffective. 3. In rat fat cells, lipolysis induced by CL 316,243 and SR 58,611A was competitively antagonized by SR 59,230A. Schild plots were linear with pA2 value of 6.89 and 6.37, respectively. Conversely, 0.1, 0.5 and 1 microM SR 59,230A did not modify the concentration-response curve of CGP 12,177. A rightward shift of the curve was however observed with 10 and 100 microM of SR 59,230A. The apparent pA2 value was 5.65. The non-selective beta-adrenergic antagonist, bupranolol, competitively displaced the concentration-response curve of CGP 12,177 and CL 316,243. Schild plots were linear with pA2 values of 6.70 and 7.59, respectively. CL316,243-mediated lipolytic effect was not antagonized by CGP 20,712A. In human fat cells, CGP 12,177-mediated lipolytic effect was antagonized by bupranolol and CGP 20,712A. SR 59,230A (0.1, 1 and 10 microM) did not modify the concentration-response curve of CGP 12,177. A rightward shift was however observed at 100 microM leading to an apparent pA2 value of 4.32. 4. The results suggest that the non-conventional partial agonist CGP 12,177 can activate lipolysis in fat cells through the interaction with a beta-adrenoceptor pharmacologically distinct from the beta 3-adrenoceptor, i.e. through a putative beta 4-adrenoceptor. They suggest that the two subtypes coexist in rat fat cells whereas only the putative beta 4-adrenoceptor mediates lipolytic effect of CGP12,177 in human fat cells.
Collapse
Affiliation(s)
- J Galitzky
- Laboratoire de Pharmacologie Médicale et Clinique, Unité 317 Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine, Université Paul Sabatier, Toulouse, France
| | | | | | | | | | | |
Collapse
|
13
|
Piétri-Rouxel F, St John Manning B, Gros J, Strosberg AD. The biochemical effect of the naturally occurring Trp64-->Arg mutation on human beta3-adrenoceptor activity. EUROPEAN JOURNAL OF BIOCHEMISTRY 1997; 247:1174-9. [PMID: 9288945 DOI: 10.1111/j.1432-1033.1997.01174.x] [Citation(s) in RCA: 104] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A Trp-->Arg mutation at amino acid position 64 in the human beta3-adrenoceptor is reportedly associated with morbid obesity; carriers suffer from increased gain in mass, early-onset diabetes, insulin resistance, and an increased waist-to-hip ratio [Clément, K., Vaisse, C., Manning, B. S., Basdevant, A., Guy-Grand, B., Ruiz, J., Silver, K. D., Shuldiner, A. R., Froguel, P. & Strosberg, A. D. (1995) N. Engl. J. Med. 333, 352-354]. Here, we report the stable expression of the genes encoding the wild-type or the [Arg64]beta3-adrenoceptor in two different cell types: hamster CHO-K1 and human HEK293. The mutated receptor displayed unchanged pharmacological values compared to the wild type for the binding inhibition (Ki) and adenylyl cyclase activation constants (K(act)) in two independent clones of both cell lines. However, maximal cAMP accumulation was significantly reduced in response to various beta3-adrenergic agonists, including endogenous catecholamines, (-)-epinephrine and (-)-norepinephrine, the non-selective agonist (-)-isoproterenol, and the beta3-adrenergic selective agonist CGP 12177A. Treatment with Pertussis toxin did not restore the adenylyl cyclase activity to that of the wild type, suggesting that the reduction in cAMP accumulation observed in cells expressing [Arg64]beta3-adrenoceptor is not due to enhanced interaction of the beta3-adrenoceptor with the inhibitory Gi protein.
Collapse
Affiliation(s)
- F Piétri-Rouxel
- Institut Cochin de Génétique Moleculaire, Laboratoire d'ImmunoPharmacologie Moléculaire, Centre Nationale de Recherche Scientifique, Paris, France
| | | | | | | |
Collapse
|
14
|
Walston J, Lowe A, Silver K, Yang Y, Bodkin NL, Hansen BC, Shuldiner AR. The beta3-adrenergic receptor in the obesity and diabetes prone rhesus monkey is very similar to human and contains arginine at codon 64. Gene 1997; 188:207-13. [PMID: 9133593 DOI: 10.1016/s0378-1119(96)00796-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The beta3-adrenergic receptor (ADRbeta3) is a seven-membrane spanning, G-protein linked receptor expressed in brown adipose tissue in rodents, and visceral adipose tissue in humans. Stimulation of the receptor by norepinephrine leads to lipolysis and thermogenesis. In rodent models of obesity and diabetes, administration of beta3-agonists results in weight loss and improved glucose tolerance. Studies indicate that the pharmacological properties of the ADRbeta3 differ markedly between rodents and humans, making generalizations of rodent studies to humans difficult. We hypothesized that the obesity and diabetes prone rhesus monkey (Macaca mulatta) would provide an excellent animal model to study the role of the ADRbeta3 in the development of obesity and diabetes as well as for assessment of the therapeutic efficacy of beta3-agonists. We sequenced the entire coding region of the rhesus ADRbeta3 gene. Like humans, the rhesus ADRbeta3 has two exons. There is 89% amino acid (aa) identity between human and rhesus compared to 82% aa identity between human and mouse. A single base deletion results in divergence of the intracellular carboxy terminus accounting for 26 of the 45 aa changes and 10 additional aa. Of the 15 rhesus monkeys studied, all were homozygous for Arg64. In humans, Arg64 (rather than Trp) is associated with increased body mass index, insulin resistance, and an earlier onset of type II diabetes mellitus. We conclude that the rhesus ADRbeta3 is more similar to the human ADRbeta3 than to the rodent ADRbeta3 suggesting that this primate model may be more appropriate for physiologic and therapeutic studies of the ADRbeta3 axis, and that Arg64 may influence susceptibility in this species to obesity, insulin resistance, and type II diabetes.
Collapse
Affiliation(s)
- J Walston
- Division of Geriatric Medicine and Gerontology, Johns Hopkins University Bayview Medical Center, Baltimore, MD 21224, USA.
| | | | | | | | | | | | | |
Collapse
|
15
|
Zilberfarb V, Piétri-Rouxel F, Jockers R, Krief S, Delouis C, Issad T, Strosberg AD. Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis. J Cell Sci 1997; 110 ( Pt 7):801-7. [PMID: 9133667 DOI: 10.1242/jcs.110.7.801] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Human brown pre-adipocytes were immortalized by microinjection of the genes encoding simian virus 40 T and t antigens under the control of the human vimentin promotor. The transfected pre-adipocytes were cultured for several months with no loss of their morphological characteristics. These cells accumulate lipids and differentiate into adipocytes when treated with insulin, triiodothyronine and dexamethazone. The mRNA of various adipocyte markers was detected by reverse transcriptase-polymerase chain reaction analysis, including hormone-sensitive lipase, lipoprotein lipase, adipsin, glucose transporters 1 and 4, the uncoupling protein (specific of brown adipocytes), and leptin, the product of the ob gene. Pharmacological analyses indicated that the beta3-adrenoceptor is the predominant beta-adrenoceptor subtype in PAZ6 cells and that this receptor subtype is functionally coupled to adenylate cyclase and lipolysis. The immortalization of human adipocytes will permit pharmacological analysis of the human beta3-adrenoceptor function in adipose cells and will allow detailed studies of human adipocyte differentiation.
Collapse
MESH Headings
- Adipocytes/chemistry
- Adipocytes/metabolism
- Adipocytes/physiology
- Adipose Tissue, Brown/chemistry
- Adipose Tissue, Brown/metabolism
- Adipose Tissue, Brown/physiology
- Adrenergic beta-Antagonists/pharmacology
- Biomarkers/analysis
- Cells, Cultured
- Cyclic AMP/analysis
- Humans
- Iodocyanopindolol
- Lipolysis/physiology
- Pindolol/analogs & derivatives
- Pindolol/metabolism
- Propanolamines/pharmacology
- Receptors, Adrenergic, beta/metabolism
- Receptors, Adrenergic, beta/physiology
- Receptors, Adrenergic, beta-3
- Transfection
Collapse
Affiliation(s)
- V Zilberfarb
- Institut Cochin de Génétique Moléculaire - Laboratoire d'Immuno-Pharmacologie Moléculaire, CNRS UPR 0415 et Université de Paris, France
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
The beta 3 subtype of adrenaline and noradrenaline receptors has now been extensively characterized at the structural and functional levels. Ligand binding and adenylyl cyclase activation studies helped define a beta-adrenergic profile that is quite distinct from that of the beta 1- and beta 2-adrenergic receptors, but strongly reminiscent of most of the "atypical" responses reported in earlier pharmacologic studies. Human, other large mammal, and rodent receptors share most of the characteristic beta 3 properties, although obvious species-specific differences have been identified. Recently, the incidence of a naturally occurring variant of the human beta 3-adrenergic receptor was shown to be correlated with hereditary obesity in Pima Indians and in Japanese individuals, and in Western obese patients with increased dynamic capacity to add on weight and develop non-insulin-dependent diabetes mellitus (NIDDM). A mild weight increase was also shown to develop in female, but not male, mice in which the beta 3 receptor gene was disrupted. Taken together, these results now provide a consistent picture of an important role of the beta 3-adrenoceptor in the regulation of lipid metabolism and as an obvious target for drugs to treat some forms of obesity.
Collapse
MESH Headings
- Adrenergic beta-Agonists/pharmacology
- Adrenergic beta-Antagonists/pharmacology
- Amino Acid Sequence
- Animals
- GTP-Binding Proteins/metabolism
- Humans
- Molecular Sequence Data
- Polymorphism, Genetic
- RNA, Messenger/metabolism
- Receptors, Adrenergic, beta/chemistry
- Receptors, Adrenergic, beta/genetics
- Receptors, Adrenergic, beta/metabolism
- Receptors, Adrenergic, beta/physiology
- Receptors, Adrenergic, beta-3
- Structure-Activity Relationship
- Tissue Distribution
Collapse
Affiliation(s)
- A D Strosberg
- Institut Cochin de Génétique Moléculaire, Laboratoire d'Immuno-Pharmacologie Moléculaire, CNRS UPR 0415, Paris, France
| |
Collapse
|
17
|
Abstract
G-protein-coupled receptors (GPCRs) are integral membrane proteins of great pharmacological importance owing to their central role in the regulation of cellular responses to external stimuli. Heterologous expression systems have been used to explore ligand binding, G protein and effector coupling, and structural aspects of the receptors. GPCRs can be expressed in a functional form in all expression systems, but with varying degrees of success because of differences in receptor and host cell characteristics. This article will discuss aspects related to the choice and suitability of expression systems for the intended analysis of GPCR properties.
Collapse
|
18
|
Abstract
The cloning, sequencing and expression in model systems of the previously unidentified beta 3-adrenoceptor recently led to an extensive functional characterization. Ligand binding and adenylate cyclase activation studies helped define a specific profile that is quite distinct from that of the beta 1- and beta 2-adrenoceptors, but strongly reminiscent of most of the 'atypical' beta-adrenoceptor-mediated responses reported in earlier pharmacological studies. More recently, a naturally occurring variation in the human beta 3-adrenoceptor has been correlated with hereditary obesity and with increased dynamic capacity to add on weight and develop non-insulin dependent diabetes in Western obese patients. Donny Strosberg and France Pietri-Rouxel describe how results now provide a consistent picture of an important role for the human beta 3-adrenoceptor in the regulation of lipid metabolism and as an obvious target for drugs to treat some forms of obesity and diabetes.
Collapse
Affiliation(s)
- A D Strosberg
- Institut Cochin de Génétique Moléculaire, CNRS UPR 0415, Paris, France
| | | |
Collapse
|
19
|
Strosberg AD. Structure, function, and regulation of the three beta-adrenergic receptors. OBESITY RESEARCH 1995; 3 Suppl 4:501S-505S. [PMID: 8697050 DOI: 10.1002/j.1550-8528.1995.tb00219.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Three beta-adrenergic receptor subtypes are now known to be functionally expressed in mammals. All three belong to the R7G family of receptors coupled to G-proteins, and characterized by an extracellular glycosylated N-terminal and an intracellular C-terminal region and seven transmembrane domains, linked by three extra- and three intracellular loops. The catecholamine ligand binding domain, studied using affinity-labeling and site-directed mutagenesis, is a pocket lined by residues belonging to the transmembrane domains. The region responsible for the interaction with the Gs protein which, when activated, stimulates adenylyl cyclase, is composed of residues belonging to the parts most proximal to the membrane of intracellular loop i3 and the C-terminal region. The pharmacology of the three subtypes is quite distinct: in fact most of the potent beta 1/beta 2 antagonists (the well known beta blockers) act as agonists on beta 3. The subtype is resistant to short-term desensitization mediated by phosphorylation through PKA or beta ARK, in stark contrast to the beta 1 or beta 2 subtypes. Various compounds (dexamethasone, butyrate, insulin) upregulate beta 1 or beta 2 subtypes while down-regulating beta 3 whose expression strictly correlates with differentiation of 3T3-F442A fibroblasts into adipocytes, thus confirming that the expression of the three subtypes may each be regulated independently to exert a specific physiologic role in different tissues or at different stages of development.
Collapse
Affiliation(s)
- A D Strosberg
- Institut Cochin de Génétique Moléculaire-Laboratoire d'Immuno-Pharmacologie Moléculaire, Paris, France
| |
Collapse
|
20
|
Pietri-Rouxel F, Strosberg AD. Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors. Fundam Clin Pharmacol 1995; 9:211-8. [PMID: 7557816 DOI: 10.1111/j.1472-8206.1995.tb00288.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Beta-adrenergic receptors (beta-AR) belong to the large multigenic family of receptors coupled to GTP-binding proteins. Three subtypes have been identified: beta 1-, beta 2- and beta 3-AR. Much of the work delineating the precise pharmacological comparison of the three beta-ARs has come from investigations with stably transfected Chinese hamster ovary cells (CHO cells). This review discusses the structure and function of beta 3-AR in various species and presents new findings on a number of beta 3-AR ligands including carazolol, tertatolol and CL 316,243 which were found to be selective and potent beta 3-AR agonists and ZD 2079 and salmeterol which appear to display full but non-subtype selective agonistic activity. Species-related variations of the beta 3-AR pharmacology have been shown for propranolol and bupranolol. With the ongoing characterization of the beta 3-AR at the molecular and cellular level, and with the advent of computer-assisted molecular modelling to aid in the determination of the three-dimensional structure of the receptor, it is thought that novel beta 3-AR compounds will become available with improved selectivity and potency.
Collapse
Affiliation(s)
- F Pietri-Rouxel
- Institut Cochin de Génétique Moléculaire, Molecular Immuno-Pharmacology Laboratory, CNRS-UPR 0415, Paris, France
| | | |
Collapse
|